Compare Charles River Laboratories Intl. Inc (CRL) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VNET Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while VNET Group Inc trades at $5.53 (market cap $1.47B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.7× VNET Group Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and VNET Group Inc for 16 Days on average.
| CRL | VNET | |
|---|---|---|
Market Cap | $14.23B | $1.47B |
Volume | 1,176,885 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $310.77 | $14.03 |
52-Week Low | $149.93 | $5.13 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $17.06B | $5.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
VNET trades at $5.17, down 4.08% today, near 52-week lows. The stock is technically bearish with weak moving averages. Fundamentally, revenue grew to $9.95B in 2025, but net losses persist with a -22.18% margin. Recent news includes a strategic investment closing and a cooperation agreement with CATL.
Outlook remains challenged by losses and high leverage, though analyst consensus is moderately bullish. Key risks include negative cash flow and execution uncertainty. The stock offers speculative appeal if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
